Evgen Pharma Share Discussion Threads

[moneymunch] 30/9/2020 10:20

and maybe disclosure on the relentless share transfer/accumulation, which possibly could be suggestive of a strategic investor JV partnership imho...Gla :-)

[jusjusjus] 30/9/2020 10:13

CEO arrives in a few days, hopefully at least an update from him for the interim period closing 30th Sept.

[notknowing] 30/9/2020 10:09

Rerate MKT CAP to 50m then 100M

[stockhunters] 30/9/2020 10:07

market makers taking it back up

ceo on board come on let us see that sfx update!

[moneymunch] 30/9/2020 09:51

SFX-01's Covid-19 patient trials are phase2/3...Gl ;-)

University of Dundee to establish potential of investigational compound to improve outcomes in COVID-19 progression in trial of 300 patients

Research title

A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in COVID-19 progression

Summary

University of Dundee and Evgen Pharma PLC, with funding from LifeArc, are set to commence clinical trial testing of an investigational medicinal product in 300 hospitalised COVID-19 patients. Researchers have identified that one of Evgen’s existing products, SFX-01, could reduce the impact of COVID-19 disease by preventing Acute Respiratory Distress Syndrome (ARDS), a common and often deadly symptom of severe cases of COVID-19.

Research organisations

University of Dundee

Evgen Pharma PLC

Researchers

Principal Investigator:

Professor James Chalmers, University of Dundee 

Co-investigators:

Albena Dinkova-Kostova, University of DundeePotential of repurposed therapeutic for COVID-19 pandemic

A major challenge in the treatment of COVID-19 is the development of slowly worsening lung damage, known as Acute Respiratory Distress Syndrome (ARDS). This requires intensive care treatment with ventilation until the inflammation is resolved and the lungs can heal.

Nrf2 is a transcription factor (a naturally-occurring protein) which forms part of the body’s defences against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. It is hypothesised that increasing the levels of active Nrf2 in patients with COVID-19 could improve recovery and prevent the need for ventilation.

SFX-01, a stable form of the natural compound sulforaphane, is an orally administered investigational medicinal product that activates Nrf2 and has been tested in over 130 patients to date in clinical trials (in healthy volunteers and patients suffering from breast cancer or a rare type of brain haemorrhage).

Researchers secured funding from LifeArc to conduct an investigator led, prospective, randomised, double-blind placebo-controlled trial, conducted in the UK, of patients hospitalised with COVID-19.

Investigating a sample size of 300 subjects, the study will compare outcomes for 300mg SFX-01 taken orally, once daily, plus best standard of care (BSC) versus placebo taken orally, once daily plus BSC. The primary outcome of the trial is the clinical status of patients on day 15 based on a seven point scale, recommended by the World Health Organisation as the optimal clinical trial endpoint for COVID-19 studies.

The trial will be conducted in up to six sites across Scotland and the north of England with first patient visit anticipated to happen in July.

[euclid5] 30/9/2020 09:20

when are EVG expecting their test results on SFX-01 - YE Dec or 1QA21 - recall this is a phase II results or just Phase I

Yes has potential to re rate if the testing results are good for SFX-01 in Covid 19 patients

Broker target price is 25p but doesn't include anything for Covid19 testing results

[awise355] 30/9/2020 09:20

That trade at 11p is a buy, my top up

[jusjusjus] 30/9/2020 08:44

it is madness, this must be realised soon!

we get a decent buy and that persistent seller just pops up again!!

what did you make of the 500k trades on Monday?

[notknowing] 30/9/2020 07:26

I document all trades.....reason for trade, target, risk levels....and all that good stuff.

I just added this:

"ps SNG's market cap rose by more than £300m on encouraging Phase 2 results for Covid-19, EVG's Phase 2 results for breast cancer were outstanding and "life changing for some patients", yet EVG's market cap sits at £15m....!!!???? ;-)"

[moneymunch] 30/9/2020 07:16

Undoubted UPside potential!!! Gla ;-)



Market opportunity in ER+ metastatic breast cancer

Incidence of ER+ metastatic breast cancer is approximately 130,0001 in US and Europe

CDK4/6 inhibitors are now first line treatment, in combination with hormone therapy

Pfizer (Ibrance®/palbociclib), Novartis (Kisqali®/ribociclib) and Eli Lilly (Versenio®/abemaciclib ) are the key players with billion plus sales - sales forecast to reach c.$9bn by 2021/2

All patients become resistant to CDK4/6 inhibitors

Treatment options post CDK4/6 inhibitors are generally poorly tolerated – treatments which improve quality of life are needed in this terminal population

Potential of SFX-01 to be treatment of choice post CDK4/6 inhibitor failure, extending progression free survival with favourable side-effect profile.

[moneymunch] 30/9/2020 07:00

ps SNG's market cap rose by more than £300m on encouraging Phase 2 results for Covid-19, EVG's Phase 2 results for breast cancer were outstanding and "life changing for some patients", yet EVG's market cap sits at £15m....!!!???? ;-)

[moneymunch] 30/9/2020 06:54

and there lies the undoubted transformational UPside potential , from this lowly share price and market cap.....all the others mentioned all started from similar positions and prospects before their stellar rises. Gla ;-)

[the stigologist] 29/9/2020 22:56

Whilst EVG is interesting and has potential please leave 4D out of your mouth.

4D is a platform technology Company with partnerships with Global Majors like Merck.

EVG has a couple of promising products but is yet to partner with any big boys.

[stockhunters] 29/9/2020 21:45

eucild

look at dddd look at sng look at fab look at acvt look at all the companies

£15m is nothing

[bocker01] 29/9/2020 20:06

Yep no more cash required and 4 different ongoing trials which are all very positive to date!

[euclid5] 29/9/2020 20:06

Quite a bit rampy & far fetched 100p target x 137m shs = £137m market cap - based on what

[stockhunters] 29/9/2020 19:23

that is why i am in prharry a good update on covid trials and £50-£100million looks likely and still cheap compared to similar companies

also nice bonus of not having to worry about cash is always good

[prharry] 29/9/2020 17:56

The great thing is that EVG will not crash, it wouldn’t have far to drop anyway and is set up for 2 years with the new deal at a minimum.
Some good/great news on any results will blow this little stock into 100p+

[moneymunch] 29/9/2020 17:40

Well he joins the BoD "early October "...so next week I guess, and hopefully along with an UPdate on proceedings and maybe disclosure on the share transfer/accumulation that seems to have been in progress, discreetly and orderly for months...Gla :-)

[bumpa33] 29/9/2020 16:40

We’ve got a long way to go to catch 4D, in more ways than one. I’m not convinced with the new man in place that we’ll get there - because I’m not sure that’s his remit.

[stockhunters] 29/9/2020 15:20

and you guessed it NCYT going ballistic again another covid company £300million market cap

just wait until we get sfx covid update tick tock

[notknowing] 29/9/2020 15:15

Watching that video should be a pre-req for investing here. We're talking Billions.

[the drewster] 29/9/2020 08:19

Anyone wanting an introduction to sulforaphane in easy to understand terms, try these:

[stockhunters] 29/9/2020 07:54

dddd into new highs

evg will not be far behind